市場調査レポート

肥満症の臨床管理:世界における製品、技術、および市場(2011年〜2019年)

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity 2011-2019

発行 MedMarket Diligence, LLC 商品コード 139886
出版日 ページ情報 英文 308 Pages; 79 Exhibits; 47 Profiles
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
肥満症の臨床管理:世界における製品、技術、および市場(2011年〜2019年) Products, Technologies and Markets Worldwide for the Clinical Management of Obesity 2011-2019
出版日: 2011年02月01日 ページ情報: 英文 308 Pages; 79 Exhibits; 47 Profiles
概要

当レポートでは、肥満症の臨床管理における技術動向、製品概要をまとめており、現在の肥満患者人口、2011年から2019年の市場発展予測、および主要企業の市場シェアを交え、概略以下の構成でお届けします。

エグゼクティブサマリー

第1章 肥満症の臨床的背景

  • 肥満症の臨床診断
  • 肥満の影響
  • エネルギー恒常性の代謝経路
  • 過体重と肥満の併存疾患
  • 世界の肥満症罹患率と患者数

第2章 肥満症の影響

  • 肥満と併存疾患の治療コスト
  • ビジネスへの影響
  • 予防と減量の規制化

第3章 過体重と肥満治療に対する臨床的アプローチ

  • 行動変革とライフスタイルの変化の役割
  • 非処方減量製品
  • 肥満症の投薬治療:過去、現在、将来の治療薬
  • 肥満症の非投薬治療

第4章 市場評価

  • 市場予測に影響を与える最近の発展
  • 世界の肥満治療市場
  • 主要企業の市場シェア
  • 南北アメリカの肥満治療市場
  • 欧州の肥満治療市場
  • アジア太平洋地域の肥満治療市場
  • その他の地域の肥満治療市場
  • 世界の肥満治療市場における戦略

第5章 企業プロファイル

第6章 治験

付録:企業ディレクトリ

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: S835

This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report profiles the 45 leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

Table of Contents

EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND OF OBESITY

  • 1.1 Clinical Diagnosis of Obesity
    • 1.1.1 Body Mass Index Scale
    • 1.1.2 Measuring BMI vs. Measuring Adiposity
    • 1.1.3 Classification of Obesity
    • 1.1.4 Overweight, Obesity, Morbid Obesity, Super Obesity
    • 1.1.5 Genetic Testing for Obesity
  • 1.2 Obesogenic Influences
    • 1.2.1 Dietary Changes Over the Last Twenty Years
    • 1.2.2 Sedentary Lifestyles
    • 1.2.3 Ongoing Research into Causes
  • 1.3 Metabolic Pathways of Energy Homeostasis
    • 1.3.1 Role of the Hypothalamus
    • 1.3.2 Role of the Stomach
    • 1.3.3 Role of the Small Intestine
    • 1.3.4 Role of the Pancreas
    • 1.3.5 Role of Adipose Tissue, An Endocrine Organ
    • 1.3.6 Other Peptides
    • 1.3.7 Obesity as Survival Mechanism
  • 1.4 Co-Morbidities of Overweight and Obesity
    • 1.4.1 Metabolic Syndrome
    • 1.4.2 Effects of Obesity on Immune Function
    • 1.4.3 Racial Differences in Co-morbidities
    • 1.4.4 Type 2 Diabetes and Insulin Resistance
    • 1.4.5 Hypertension
    • 1.4.6 Dyslipidemia
    • 1.4.7 Depression
    • 1.4.8 Osteoarthritis
    • 1.4.9 Asthma
    • 1.4.10 Sleep apnea
    • 1.4.11 Obesity and Cancer
  • 1.5 Global Incidence and Prevalence of Obesity
    • 1.5.1 By Geographic Region
      • 1.5.1.1 USA, Canada, Mexico, Brazil
      • 1.5.1.2 European Union
      • 1.5.1.3 Asia-Pacific
    • 1.5.2 By Age Group
      • 1.5.2.1 Incidence and Prevalence among Children
      • 1.5.2.2 Incidence and Prevalence among Elderly
    • 1.5.3 Incidence and Prevalence of Morbid Obesity

SECTION 2: THE IMPACT OF OBESITY

  • 2.1 Costs Related to Treating Obesity and Co-Morbidities
    • 2.1.1 Current Healthcare Expenses
      • 2.1.1.1 Spending in the USA
      • 2.1.1.2 Outside of the U.S., Spending Also Rising
    • 2.1.2 The Looming Wave of Type 2 Diabetes
  • 2.2 Impact on Businesses
    • 2.2.1 Increased Health and Life Insurance Costs
    • 2.2.2 Increased Costs Shouldered by Employers
    • 2.2.3 Debate: Pay Employees to Lose Weight?
  • 2.3 Legislating Prevention and Weight Loss
    • 2.3.1 Healthcare Reform and Obesity
    • 2.3.2 Changing Society
    • 2.3.3 Pressure on the Food Industry

SECTION 3: CLINICAL APPROACHES TO THE TREATMENT OF OVERWEIGHT AND OBESITY

  • 3.1 Role of Behavior Modification and Lifestyle Changes
    • 3.1.1 Behavior Modification with Pharmacotherapies
    • 3.1.2 Specialists' Use of Pharmaceuticals
    • 3.1.3 Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
    • 3.1.4 Why Diets Usually Fail
    • 3.1.5 The Diogenes Study' s Dietary Recommendations
  • 3.2 Non Prescription Weight Loss Products
  • 3.3 Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs
    • 3.3.1 The US FDA' s Guidance for Industry Developing Products for Weight Management
    • 3.3.2 Definition of Satiety vs. Appetite Suppression
    • 3.3.3 Definition of Combination Drugs
    • 3.3.4 The Bloom is Off the Rose: Promising Drugs Which Have Failed, and Why
      • 3.3.4.1 Phentermine/Fenfluramine Combination
      • 3.3.4.2 Abbott' s Meridia (Sibutramine)
      • 3.3.4.3 Vivus' Qnexa: Out for Good?
      • 3.3.4.4 Arena' s Lorqess: Not out of the picture yet
    • 3.3.5 Prescription Drugs Currently on the Market
      • 3.3.5.1 Appetite Suppression Drugs
      • 3.3.5.2 Malabsorption Drugs
      • 3.3.5.3 Satiety Drugs
      • 3.3.5.4 Combination Drugs
    • 3.3.6 Areas of Pharmaceutical Research
      • 3.3.6.1 Melanocortin Receptor System
      • 3.3.6.2 Cannabinoid Receptor Antagonists
      • 3.3.6.3 GLP-1 Analogs
      • 3.3.6.4 Methionine Aminopeptidase 2 (MetAP2) Inhibitor
      • 3.3.6.5 Appetite Suppression Drugs
      • 3.3.6.6 Malabsorption Drugs
      • 3.3.6.7 Satiety Drugs
      • 3.3.6.8 Combination Drugs
    • 3.3.7 Safety: The Major Diet Drug Hurdle
  • 3.4 Non- Pharmaceutical Options for Treating Obesity
    • 3.4.1 Metabolic/Bariatric Surgery
      • 3.4.1.1 Buchwald and Oien Research, 2009
      • 3.4.1.2 Vertical Banded Gastroplasty
      • 3.4.1.3 Roux-en-Y Surgery
      • 3.4.1.4 Sleeve Gastrectomy
      • 3.4.1.5 Biliopancreatic Diversion with Duodenal Switch
      • 3.4.1.6 Jejuno-ileal Bypass: An Obsolete Procedure
    • 3.4.2 Devices to Treat Obesity
      • 3.4.2.1 Restrictive Devices
      • 3.4.2.2 Artificial Fullness Devices
      • 3.4.2.3 Malabsorption Devices
      • 3.4.2.4 Devices to Control Gastric Emptying
      • 3.4.2.5 Appetite Suppressive Devices
      • 3.4.2.6 Gastric Electrical Stimulation

SECTION 4: MARKET ASSESSMENT

  • 4.1 Recent Developments Impacting Market Forecasts
  • 4.2 Anticipated Developments Underlying the Market Forecast
  • 4.3 Global Market for Obesity Treatments
    • 4.3.1 Pharmaceuticals
    • 4.3.2 Devices
  • 4.4 Market Shares of Leading Companies
    • 4.4.1 Leading Pharmaceutical Companies
    • 4.4.2 Leading Device Companies
  • 4.5 Americas Market for the Treatment of Obesity
    • 4.5.1 USA
    • 4.5.2 Canada
    • 4.5.3 Mexico
    • 4.5.4 Brazil
  • 4.6 European Market for the Treatment of Obesity
    • 4.6.1 United Kingdom
    • 4.6.2 Germany
    • 4.6.3 France
    • 4.6.4 Spain
    • 4.6.5 Italy
    • 4.6.6 Rest of Europe
  • 4.7 Asia-Pacific Markets for the Treatment of Obesity
    • 4.7.1 Japan
    • 4.7.2 China
    • 4.7.3 India
    • 4.7.4 Australia
  • 4.8 ROW Markets for the Treatment of Obesity
  • 4.9 Strategies in the Global Obesity Market
    • 4.9.1 Market Drivers
      • 4.9.1.1 Significant Unmet Needs
      • 4.9.1.2 The Need for a Variety of Treatment Options
      • 4.9.1.3 Device Opportunity Grows Due to Lack of Drugs
      • 4.9.1.4 Healthcare Reform
      • 4.9.1.5 Treating Obesity to Avoid Costly Co-Morbidities
    • 4.9.2 Market Restraints
      • 4.9.2.1 Intense Complexity of the Metabolic Regulatory System
      • 4.9.2.2 Time, Costs, Risks Involved in Developing a More Efficacious Drug
      • 4.9.2.3 Tightening of Safety Requirements for Obesity Drugs
      • 4.9.2.4 Data Showing Lack of Sustainable Weight Loss with Gastric Banding
      • 4.9.2.5 Lack of Reimbursement
    • 4.9.3 Strategies for Market Success

SECTION 5: COMPANY PROFILES

  • 5.1 7TM Pharma
  • 5.2 Abbott Laboratories
  • 5.3 Allergan
  • 5.4 Amylin Pharmaceuticals
  • 5.5 Arena Pharmaceuticals
  • 5.6 AstraZeneca
  • 5.7 BAROnova Therapeutics
  • 5.8 BaroSense
  • 5.9 BFKW, LLC (c/o Legacy Capital Advisors, LLC)
  • 5.10 Covidien
  • 5.11 CR Bard, Inc.
  • 5.12 Crospon, Inc.
  • 5.13 Eli Lilly & Company
  • 5.14 EndoGastric Solutions
  • 5.15 EndoSphere
  • 5.16 EnteroMedics, Inc.
  • 5.17 Ethicon Endo-Surgery, Inc. (JNJ)
  • 5.18 Gelesis, Inc.
  • 5.19 GI Dynamics
  • 5.20 GlaxoSmithKline
  • 5.21 Helioscopie
  • 5.22 Interleukin Genetics
  • 5.23 IntraPace
  • 5.24 Laboratoire Endalis
  • 5.25 Merck
  • 5.26 MetaCure
  • 5.27 Nestle Healthcare Nutrition
  • 5.28 NeuroSearch A/S
  • 5.29 Novo Nordisk
  • 5.30 Orexigen Therapeutics, Inc.
  • 5.31 Pfizer, Inc.
  • 5.32 ReShape Medical
  • 5.33 Rhythm Pharmaceuticals
  • 5.34 SafeStitch Medical, Inc.
  • 5.35 Sanofi-Aventis
  • 5.36 Satiety, Inc.
  • 5.37 Scientific Intake, LLC
  • 5.38 Shionogi & Co., Ltd.
  • 5.39 Silhouette Medical, Inc.
  • 5.40 Spatz FGIA, Inc.
  • 5.41 Surface Logix, Inc.
  • 5.42 USGI Medical
  • 5.43 ValenTx, Inc.
  • 5.44 Verva Pharmaceuticals Ltd.
  • 5.45 Vivus, Inc.
  • 5.46 Zafgen, Inc.

SECTION 6: CLINICAL TRIALS

APPENDIX: COMPANY DIRECTORY

List of Exhibits

  • Exhibit ES-1: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010
  • Exhibit ES-2: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries
  • Exhibit ES-3: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
  • Exhibit ES-4: Regional Percent Revenue Shares, 2009
  • Exhibit ES-5: Manufacturer Percent Revenue Shares, Global Obesity Market, 2009
  • Exhibit 1-1: Calculation of Body Mass Index (BMI)
  • Exhibit 1-2: Proposed WHO Classification of BMI in Adult Asians
  • Exhibit 1-3: The International BMI Classification of Adult Underweight, Overweight and Obesity According to the World Health Organization (WHO)
  • Exhibit 1-4: The Human Gastrointestinal Tract
  • Exhibit 1-5: From Chronic Energy Imbalance to Co-Morbidities
  • Exhibit 1-6: Relative Risk of Mortality by BMI in US Men
  • Exhibit 1-7: Relative Risk of Mortality by BMI in US Women
  • Exhibit 1-8: World Incidence and Prevalence for Cancers Associated with Obesity
  • Exhibit 1-9: AICR Estimated Cases Per Year of Cancers Linked to Excss Body Fat
  • Exhibit 1-10: Populations and Rates of Obesity of Selected Countries, 2009
  • Exhibit 1-11: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010
  • Exhibit 1-12: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries
  • Exhibit 1-13: Percent of Adults Who are Overweight/Obese, by Country, 2010
  • Exhibit 1-14: USA Obesity Prevalence by State, 2004.
  • Exhibit 1-15: USA Obesity Prevalence by State, 2009.
  • Exhibit 1-16: Prevalence of Obesity in Canada for 1978-2005 (Measured Values)
  • Exhibit 1-17: Prevalence of Overweight and Obesity in Women and Men in Mexico from a Nationally Representative Sample and a Sample of Low-Income Rural Mexicans
  • Exhibit 1-18: WHO Prevalence of Obesity by Sex, Adults Aged 15 and Over, Latest Available Year, Europe
  • Exhibit 1-19: States of India ranked by percentage of overweight or obese (2006)
  • Exhibit 1-20: Percent of Children in Select Age Groups and Countries Who are Overweight (Including Obese), 2010
  • Exhibit 3-1: FDA List of Tainted Weight Loss Products, March 2009
  • Exhibit 3-2: Companies with Obesity Pharmaceuticals on Market or in Development, 2010
  • Exhibit 3-3: Number Of Bariatric Surgeons and Bariatric Surgery Operations, 2008
  • Exhibit 3-4: Global Trend in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-5: Global Trends in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-6: Regional Trend in Metabolic/Bariatric Surgery, USA/Canada, 2003-2008
  • Exhibit 3-7: USA/Canada Trends in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-8: Regional Trends in Metabolic/Bariatric Surgery, Europe, 2003-2013
  • Exhibit 3-9: European Trends in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-10: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013
  • Exhibit 3-11: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013
  • Exhibit 3-12: Regional Trend in Metabolic/Bariatric Surgery, Rest of World, 2003-2013
  • Exhibit 3-13: Regional Trends in Metabolic/Bariatric Surgery, Rest of World, 2003-2013
  • Exhibit 3-14: Companies with Obesity Devices on Market or in Development, 2010
  • Exhibit 4-1: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
  • Exhibit 4-2: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
  • Exhibit 4-3: Total Modality Market Shares by Percent Revenues, 2009
  • Exhibit 4-4: Total Modality Market Shares by Percent Revenue, 2019
  • Exhibit 4-5: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-6: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-7: Global Market for Device Treatment of Obesity, 2009-2019, (USD Millions)
  • Exhibit 4-8: Global Market for Medical Device Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-9: Percent Revenue Shares, Global Obesity Market, 2009
  • Exhibit 4-10: Percent Revenue Shares, Global Anti-Obesity Drug Market, 2009
  • Exhibit 4-11: Percent Revenue Shares, Global (Off-Label) Satiety Drug Market, 2009
  • Exhibit 4-12: Percent Revenue Shares, Global Pharmaceutical Appetite Suppression Market, 2009
  • Exhibit 4-13: Percent Revenue Shares, Global Anti-Obesity Devices Market, 2009
  • Exhibit 4-14: Percent Revenue Shares, Global Restrictive Devices Market, 2009
  • Exhibit 4-15: Percent Revenue Shares, Global Artificial Fullness Devices Market, 2009
  • Exhibit 4-16: Percent Revenue Shares, Global Appetite Suppression Devices Market, 2009
  • Exhibit 4-17: Americas Market for Treatment of Obesity, 2009-2019
  • Exhibit 4-18: Americas Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-19: USA Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-20: Canada Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-21: Mexico Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-22: Brazil Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-23: European Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-24: EU Obesity Percent Revenue Market Shares by Country, 2009
  • Exhibit 4-25: EU Obesity Percent Revenue Market Shares by Country, 2019
  • Exhibit 4-26: European Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-27: UK Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-28: Trends in Gastric Bypass vs. Gastric Banding, England, 2000-2007
  • Exhibit 4-29: Germany Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-30: France Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-31: Spain Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-32: Italy Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-33: Rest of Europe Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-34: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-35: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-36: Japan Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-37: China Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-38: India Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-39: Australia Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-40: Rest of World Market for Treatment of Obesity, 2009-2019 (USD Millions)
Back to Top